XML 87 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 29, 2018
Dec. 17, 2018
Jul. 30, 2013
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2015
Jun. 30, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Unbilled contract asset       $ 180,000 $ 0    
AstraZeneca Agreements [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Transaction price and allocated to performance obligations             $ 50,000
Revenue during period from performance obligations       42,400      
Unbilled contract asset       50,000      
AstraZeneca Agreements [Member] | U.S./RoW [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront, non-contingent, non-refundable and time-based payments     $ 374,000        
Potential milestone payments     875,000        
Commercial sales milestone     325,000        
Aggregate consideration received       $ 389,000      
Shared development costs           $ 233,000  
Additional consideration based on net sales description       low 20% range      
Unbilled contract asset       $ 50,000      
AstraZeneca Agreements [Member] | U.S./RoW [Member] | FibroGen, Inc. [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Shared development costs           116,500  
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Clinical and Development Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments     65,000        
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Regulatory Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments     325,000        
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Deferred Approval Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments     160,000        
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Development Milestones [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Receipt of development milestone payment           $ 15,000  
AstraZeneca Agreements [Member] | China [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments     348,500 22,000      
Aggregate consideration received       55,200      
Proceeds from upfront, non-contingent and non-refundable payments     28,200        
Commercial sales and other events milestone     187,500        
Contract with customer, liability, revenue recognized       $ 18,700      
Estimated joint development extended service period       2024      
Milestone payment, revenue recognition $ 6,000 $ 6,000   $ 12,000 $ 9,900    
AstraZeneca Agreements [Member] | China [Member] | Clinical and Development Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments     15,000        
AstraZeneca Agreements [Member] | China [Member] | Regulatory Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments     $ 146,000